Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.

Yonsei medical journal - 1 May 2017

Kim Dong Hyun, Choi Jong Won, Seo Jeong Hun, Cho Yong Suk, Won Sun Young, Park Byung Kyu, Jeon Han Ho, Shin Sang Yun, Lee Chun Kyon

Abstract excerpt

PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. MATERIALS AND METHODS: Sixty subjects were randomized to continue with ETV or switch to LdT. Significant difference in baseline characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B, Chronic
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Substitution

Share to Guanine

Share to Hepatitis B virus

Share to Thymidine

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 28332360
DOI: 10.3349/ymj.2017.58.3.552
PMCID: PMC5368140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.PMID 28332360Read ↗

Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.Semantic proximity Read ↗

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Semantic proximity Read ↗

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.Semantic proximity Read ↗

Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Semantic proximity Read ↗

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.Semantic proximity Read ↗

Entecavir resistance is rare in nucleoside naïve patients with hepatitis BSemantic proximity Read ↗

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.Semantic proximity Read ↗

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.